Shares of WW International (NASDAQ:WW) have reversed Thursday’s after-hours gains as guarded remarks from the company’s CEO ...

“GLP-1 receptor agonist use was not associated with an increased risk of suicidal ideation, self-harm, or suicide” compared ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

Nearly one-third of adult employees would change jobs in order to gain coverage. As the demand for GLP-1 weight loss ...

Sara Burnett, executive director of non-profit ReFED, on food waste in the US, government policies, and the impact of AI and ...

The agriculture community needs to focus on the implications of the use of weight-loss drugs and the world reaching “peak” ...

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names ...

Ozempic and its ilk may do a lot of things, but raising the risk of suicide doesn’t appear to be one of them. Research out ...

Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and Ozempic, could have “an antidepressant effect,” suggesting ...

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...